• Investor Home
  • Apollo Endosurgery, Inc. to Report First Quarter Results on May 3, 2018

Apollo Endosurgery, Inc. to Report First Quarter Results on May 3, 2018

Thursday, April 26, 2018 3:01 pm CDT

Public Company Information:

NASDAQ:
APEN

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it plans to release its financial results for the first quarter ended March 31, 2018 on Thursday, May 3, 2018, after the U.S. stock markets close.

Apollo will hold a conference call on Thursday, May 3, 2018 at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (800) 239-9838 for domestic callers and (323) 794-2551 for international callers. The conference ID number is 7312360. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.apolloendo.com.

A replay of the webcast will remain available on Apollo’s website, www.apolloendo.com, until Apollo releases its second quarter 2018 financial results. In addition, a telephonic replay of the call will be available until May 10, 2018. The replay dial-in numbers are (844) 512-2921 for domestic callers and (412) 317-6671 for international callers. Please use the replay conference ID number 7312360.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today.

Apollo’s common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, visit: www.apolloendo.com.

Contact:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
Chief Financial Officer
investor-relations@apolloendo.com
or
The Ruth Group
Lee Roth, 646-536-7000
apolloendo@theruthgroup.com

Business Wire InvestorHQ℠